Safety and Efficacy of Ibritumomab Tiuxetan (Zevalin) Association With a Fludarabine Based Reduced Conditioning Regimen [fludarabine, busulfan, antithymocyte globulin, ciclosporin and rituximab] and Allogenic Stem Cell Support in Chemo-sensitive Relapsed CD20 Positive Aggressive Non-Hodgkin's Lymphoma Patients.

Trial Profile

Safety and Efficacy of Ibritumomab Tiuxetan (Zevalin) Association With a Fludarabine Based Reduced Conditioning Regimen [fludarabine, busulfan, antithymocyte globulin, ciclosporin and rituximab] and Allogenic Stem Cell Support in Chemo-sensitive Relapsed CD20 Positive Aggressive Non-Hodgkin's Lymphoma Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2014

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Antithymocyte globulin; Busulfan; Busulfan; Ciclosporin; Fludarabine; Rituximab
  • Indications Diffuse large B cell lymphoma; Graft-versus-host disease; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Dec 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 12 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top